Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

3(37.5%)

Phase 3

3(37.5%)

N/A

1(12.5%)

Phase 1

1(12.5%)

8Total

Phase 2(3)

Phase 3(3)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07342439Phase 3Not Yet Recruiting

Study of Serine Supplementation to Protect Vision in MacTel

Role: lead

NCT04729972Phase 2Completed

Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2

Role: collaborator

NCT03316300Phase 3Completed

A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A

Role: collaborator

NCT03319849Phase 3Completed

A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B

Role: collaborator

NCT04907084Phase 2Active Not Recruiting

Serine and Fenofibrate Study in Patients With MacTel Type 2

Role: lead

NCT03321916Not ApplicableCompleted

MacTel Laser Study

Role: lead

NCT01949324Phase 2Completed

A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel

Role: collaborator

NCT01327911Phase 1Completed

Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)

Role: collaborator

NCT00568828Unknown

MPOD in Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin

Role: lead

All 9 trials loaded